GRP logo
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report-Part II

The citation for this report is:
Garrison Jr. LP, Mansley EC, Abbott III TA, et al. Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report-Part II. Value Health 2010;13:8-13.

Translations: » 中文

Task Force Leadership Group
Lou Garrison PhD, Societal Subgroup Chair & Professor and Associate Director, Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA
Edward C. Mansley PhD, Associate Director, Health Economics, U.S. Outcomes Research, Merck & Co., Inc., North Wales, PA, USA
Thomas A. Abbott, III PhD, MBA, President, i3 Pharma Informatics, Horsham, PA, USA
Brian Bresnahan PhD, Research Assistant Professor, Department of Radiology, University of Washington, Seattle, WA, USA

For recommendations on how drug costs should be measured for cost-effectiveness analysis from other key analytic perspectives, please refer to the following reports:

FINAL REPORT
The Drug Cost Standards Task Force presented their reports including responses to member comments during an open forum at ISPOR’s 14th Annual International Meeting in Orlando, FL in May 2009.  The task force’s forum presentation can be viewed at: Forum Presentation


ISPOR Good Practices For Outcomes Research Index